Prudential Financial Inc. Buys 27,800 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Prudential Financial Inc. lifted its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 76.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 64,300 shares of the biotechnology company’s stock after buying an additional 27,800 shares during the period. Prudential Financial Inc.’s holdings in CytomX Therapeutics were worth $66,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CTMX. Monimus Capital Management LP acquired a new position in shares of CytomX Therapeutics during the 4th quarter worth approximately $375,000. Virtu Financial LLC bought a new position in shares of CytomX Therapeutics in the third quarter valued at $104,000. FMR LLC grew its stake in shares of CytomX Therapeutics by 17.3% in the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 41,949 shares in the last quarter. Geode Capital Management LLC increased its holdings in CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after buying an additional 34,032 shares during the last quarter. Finally, Traphagen Investment Advisors LLC bought a new stake in CytomX Therapeutics during the fourth quarter worth $31,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Trading Up 7.7 %

CytomX Therapeutics stock opened at $0.53 on Friday. The company has a market capitalization of $42.65 million, a price-to-earnings ratio of 3.13 and a beta of 1.34. CytomX Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $5.85. The stock’s 50 day moving average is $0.66 and its 200-day moving average is $0.90.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. As a group, equities research analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of CytomX Therapeutics in a research note on Friday, March 7th. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Finally, StockNews.com cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 31st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $5.02.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.